In 2018, the International Council for Standardization in Haematology (ICSH) published a
consensus document providing guidance for laboratories on measuring direct oral …

This guidance document was prepared on behalf of the International Council for
Standardization in Haematology (ICSH) for providing haemostasis-related guidance …

A new generation of antithrombotic agents, which are conventionally known as direct oral
anticoagulants (DOACs), have recently emerged and are continuing to be developed. These …

The first direct oral anticoagulant (DOAC) to be approved for clinical use was dabigatran, a
direct thrombin inhibitor, in 2010. Since that time, four additional DOACs, all direct anti‐Xa …

Click to hear Dr Baglin's perspective on the role of the laboratory in treatment with new oral
anticoagulants Summary One of the key benefits of the direct oral anticoagulants (DOACs) is …

The introduction of direct oral anticoagulant (DOAC) therapy into clinical use in the past 5
years has had significant impact on the clinical laboratory. Clinicians' desire to determine …

Although the direct oral anticoagulants (DOACs) do not require routine monitoring and
reduce bleeding compared with warfarin, there are special circumstances in which …

Direct oral anticoagulants (DOACs) are increasingly used in the treatment and prophylaxis
of thromboembolism because of several advantages over vitamin K antagonists, including …

Background There is an increasing amount of literature on direct oral anticoagulant (DOAC)
laboratory monitoring. The aims of the present review were to evaluate published data on …

The direct acting oral anticoagulants (DOAC s), including dabigatran, rivaroxaban,
apixaban, and edoxaban, have favorable pharmacokinetic and pharmacodynamic …